Wednesday, July 15, 2020 - 9:30 am to 12:00 noon EDT

9:30 – 9:35 am  
Welcome & Opening Remarks  
Symposium Co-Chairs Richard Stone, MD, Dana-Farber Cancer Institute and Neal Young, MD, National Heart, Lung, and Blood Institute

9:35 – 10:00 am  
Acquired abnormalities in BMF – focus on HLA mutations  
Daria Babushok, MD, PhD, University of Pennsylvania

10:00 – 10:30 am  
Novel syndromes predisposing to BMF/MDS  
Marcin Wlodarski, MD, PhD, St. Jude Children’s Research Hospital

10:30 – 11:00 am  
Germline predisposition in late onset BMF/MDS  
Jaroslaw Maciejewski, MD, PhD, Cleveland Clinic

11:00 – 11:30 am  
Mechanisms of Somatic Transformation in SDS Patients  
R. Coleman Lindsley, MD, PhD, Dana-Farber Cancer Institute

11:45 – 12:00 pm  
Session Discussion
Thursday, July 16 – 9:30 am to 12:00 noon EDT

**Transplantation for Bone Marrow Failure**

*Co-Chairs: H. Joachim Deeg, MD, Fred Hutchinson Cancer Center\nAntonio Risitano, MD, PhD, University of Naples*

9:30 – 10:00 am  Conventional and Haplo-identical transplants
Amy E. DeZern, MD, MHS, Johns Hopkins

10:00 – 10:30 am  Transplantation for Inherited Bone Marrow Failure Disorders and Fanconi Anemia
Carmen Bonfim, MD, PhD, University of Parana

**Non-transplant Therapies for Marrow Failure**

*Co-Chairs: Phillip Scheinberg, MD, University of Sao Paulo and Neal Young, MD, NHLBI*

10:30 – 10:45 am  RACE Study Update
Antonio Risitano, MD, PhD, University of Naples

10:45 – 11:15 am  NIH Long Term Follow-up
Bhavisha Patel, MD, National Heart, Lung, and Blood Institute

11:15 – 11:45 am  Future Directions in Non-Transplant Therapies
Phillip Scheinberg, MD, University of Sao Paulo and Neal Young, MD, NHLBI

11:45 – 12:00 pm  Session Discussion
Friday, July 17 – 9:30 am to 12:00 noon EDT

**Treatments for MDS and Secondary AML**

*Co-Chairs: Olatoyosi Odenike, MD, University of Chicago and David Sallman, MD, Moffitt Cancer Center*

9:30 – 10:00 am  **Novel strategies for TP53 mutated AML/MDS**
David Sallman, MD, Moffitt Cancer Center

10:00 – 10:30 am  **TGF beta inhibition in MDS**
Amit Verma, MD, Albert Einstein College of Medicine

10:30 – 11:00 am  **Spliceosome modulation as a target in MDS**
Timothy Graubert, MD, Massachusetts General Hospital

11:00 – 11:30 am  **Oral azanucleosides and novel combination strategies in higher risk MDS**
Olatoyosi Odenike, MD, University of Chicago

11:30 – 12:00 noon  **Session Discussion**